When Red Cells Break Too Soon: Navigating Hereditary Hemolytic Anemia in Childhood
1. Bharti Chavhan
2. Osmonova Gulnaz Zhenishbaevna
(1. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic
2. Teacher, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.)
Abstract
Hereditary hemolytic anemias arise from intrinsic red-cell defects that shorten erythrocyte survival and place a lifelong burden on affected children. Membrane disorders, enzyme deficiencies, and hemoglobinopathies remain the principal categories, each with distinct clinical rhythms and management needs. Recent advances in genetic diagnosis, disease-modifying agents such as hydroxyurea and pyruvate-kinase activators, and the emergence of gene therapy have reshaped care, yet timely recognition and supportive strategies still determine developmental and long-term outcomes. This review synthesizes current understanding of pathophysiology, diagnosis, and treatment for the practicing pediatrician and trainee.
Introduction
A newborn who develops jaundice within hours of birth, a toddler whose spleen becomes palpable during a viral illness, or an adolescent who presents with unexplained fatigue and gallstones may all share the same underlying problem: red cells that cannot survive the ordinary stresses of circulation. Hereditary hemolytic anemias encompass a diverse group of disorders caused by mutations affecting the red-cell membrane, its metabolic enzymes, or the hemoglobin molecule itself. Although individual conditions are often rare, collectively they constitute a significant share of pediatric hematologic disease worldwide and carry risks that extend far beyond anemia—neonatal hyperbilirubinemia with potential kernicterus, growth failure, iron overload, thromboembolism after splenectomy, and, in the case of sickle cell disease, progressive organ damage.
The past decade has brought meaningful progress. Next-generation sequencing has shortened the diagnostic odyssey, hydroxyurea is now recommended for nearly all children with sickle cell anemia, the first pyruvate-kinase activator has entered clinical use, and gene therapies for sickle cell disease have moved from experimental to approved. Yet the fundamental clinical challenge remains unchanged: recognizing the child whose red cells are fragile before irreversible complications appear, and then matching therapy to the specific molecular lesion and the family’s capacity to sustain long-term care. This article reviews the major hereditary hemolytic anemias of childhood within the IMRAD framework, emphasizing practical diagnostic pathways and evidence-based management as of 2026.
Methods
This narrative review draws on recent clinical guidelines, systematic reviews, and key primary studies published or updated through mid-2026. Sources include the World Health Organization consolidated guidelines on sickle-cell disease in children and adolescents, consensus recommendations on red-cell membrane disorders, and contemporary reviews of pyruvate-kinase deficiency and glucose-6-phosphate dehydrogenase deficiency. Emphasis is placed on literature that addresses pediatric presentation, laboratory diagnosis, and therapeutic advances rather than purely molecular or adult-focused data. No original patient data were collected; the synthesis aims to provide a coherent clinical overview for university-level medical education and practice.
Results
Classification and Pathophysiology
Hereditary hemolytic anemias are customarily grouped by the site of the intrinsic defect. Membrane disorders result from mutations that disrupt vertical or horizontal linkages within the red-cell cytoskeleton. Hereditary spherocytosis, the most common membrane disorder in populations of Northern European ancestry, arises predominantly from heterozygous mutations in ANK1, SPTB, or SLC4A1; loss of surface area produces rigid spherocytes that are trapped and destroyed in the spleen. Hereditary elliptocytosis and its severe variant hereditary pyropoikilocytosis stem from defects in horizontal interactions, most often involving SPTA1 or SPTB, and can present with striking poikilocytosis and transfusion dependence from birth.
Enzyme deficiencies impair the red cell’s ability to generate ATP or to defend against oxidative stress. Glucose-6-phosphate dehydrogenase deficiency, an X-linked disorder affecting hundreds of millions worldwide, leaves erythrocytes vulnerable to hemolysis when exposed to infection, certain foods such as fava beans, or oxidant drugs. Pyruvate-kinase deficiency, an autosomal recessive disorder of the glycolytic pathway, reduces ATP production, shortens red-cell survival, and is characterized by elevated 2,3-diphosphoglycerate that paradoxically improves tissue oxygen delivery despite anemia.
Hemoglobinopathies form the third major category. Sickle cell disease, caused by the Glu6Val substitution in the beta-globin gene, produces polymerization of deoxygenated hemoglobin, vaso-occlusion, and chronic hemolysis. Thalassemias result from quantitative defects in globin-chain synthesis and generate ineffective erythropoiesis as well as hemolysis of residual red cells. Unstable hemoglobin variants may also produce chronic or episodic hemolysis, though they are less common.
Clinical Presentation
Severity ranges from silent carrier states to life-threatening neonatal anemia. Many infants with severe membrane disorders or pyruvate-kinase deficiency present with jaundice requiring phototherapy or exchange transfusion in the first days of life. Milder forms of hereditary spherocytosis may escape notice until a viral infection triggers an aplastic or hemolytic crisis, or until gallstones appear in later childhood. Children with glucose-6-phosphate dehydrogenase deficiency typically experience acute intravascular hemolysis after a precipitant, with dark urine, back pain, and a rapid fall in hemoglobin; between episodes they may be entirely well.
Sickle cell disease follows a different tempo. After the physiologic decline of fetal hemoglobin, vaso-occlusive pain, acute chest syndrome, and risk of stroke emerge, while chronic hemolysis drives progressive organ injury. Growth faltering, delayed puberty, and increased susceptibility to infection remain common even with modern supportive care. Across all these disorders, the spleen plays a central role: splenomegaly is frequent, hypersplenism can exacerbate anemia, and functional or surgical asplenia markedly elevates the risk of overwhelming bacterial sepsis.
Laboratory Diagnosis
The laboratory evaluation begins with a complete blood count, reticulocyte count, and peripheral-blood smear. Elevated reticulocytes, indirect hyperbilirubinemia, low haptoglobin, and increased lactate dehydrogenase confirm hemolysis. Spherocytes, elliptocytes, bite cells, blister cells, or sickle forms guide the differential. The direct antiglobulin test is essential to exclude immune hemolysis, which can coexist with or mimic hereditary disease.
Specialized testing then narrows the diagnosis. Osmotic fragility or the eosin-5-maleimide binding assay supports hereditary spherocytosis; ektacytometry provides characteristic deformability curves that distinguish membrane disorders from one another and from hereditary xerocytosis. Enzyme assays for glucose-6-phosphate dehydrogenase and pyruvate kinase remain useful, although they must be interpreted cautiously during or immediately after a hemolytic episode when younger red cells may yield falsely normal results. Ultimately, targeted or broad next-generation sequencing panels have become the confirmatory standard, identifying the causative variants, clarifying inheritance patterns, and guiding genetic counseling. In transfusion-dependent infants, molecular testing may be the only reliable route to a precise diagnosis.
Management
Supportive care remains the foundation for most children. Folic acid supplementation supports the heightened erythropoietic demand. Transfusion is reserved for symptomatic anemia or for specific indications such as stroke prevention in sickle cell disease; over-transfusion risks iron overload and alloimmunization. Newborns with severe jaundice require prompt phototherapy and, when necessary, exchange transfusion to prevent kernicterus.
Disease-specific interventions have expanded. In hereditary spherocytosis of moderate or greater severity, splenectomy after the age of five to six years substantially reduces hemolysis and transfusion need, provided that appropriate vaccination and lifelong antibiotic prophylaxis are ensured. Partial splenectomy is sometimes considered in younger children to preserve residual immune function. In pyruvate-kinase deficiency, the oral allosteric activator mitapivat has demonstrated efficacy in adults and is under active pediatric investigation; splenectomy remains an option for transfusion-dependent children once the diagnosis is genetically confirmed.
For sickle cell disease the landscape has changed markedly. The World Health Organization now recommends hydroxyurea for all children with sickle cell anemia from nine months of age onward, regardless of clinical severity, because of its consistent reduction in vaso-occlusive events, acute chest syndrome, and transfusion requirement. Newer agents targeting polymerization, adhesion, or inflammation are available or in late-stage trials, while two gene therapies received regulatory approval in 2023 and continue to accumulate real-world pediatric experience. Allogeneic hematopoietic stem-cell transplantation remains the only widely available curative modality and is increasingly considered earlier in the disease course when a matched sibling donor is available.
Prevention of secondary complications is equally critical. Children with functional or surgical asplenia require pneumococcal, meningococcal, and Haemophilus influenzae type b vaccination and penicillin prophylaxis at least through early childhood. Regular screening for iron overload, pulmonary hypertension, retinopathy, and nephropathy is standard in transfusion-dependent or sickle-cell populations. Transition programs that prepare adolescents for adult care help preserve the gains achieved in pediatric centers.
Discussion
Hereditary hemolytic anemias illustrate both the power and the limits of modern pediatric hematology. Molecular diagnosis has largely replaced empiric labeling, allowing precise counseling and, in some cases, genotype-directed therapy. Disease-modifying drugs and gene therapies have transformed the outlook for sickle cell disease and hold promise for rarer enzymopathies. Yet the majority of affected children worldwide still lack access to these advances; hydroxyurea remains underutilized in many high-burden regions, and gene therapy is currently available only in specialized centers.
Several practical lessons emerge for the clinician. First, a careful family history and examination of the blood film remain indispensable; sophisticated testing cannot replace clinical suspicion. Second, the decision to perform splenectomy must weigh the reduction in hemolysis against lifelong infection risk and, in certain membrane disorders such as hereditary xerocytosis, an increased thrombotic tendency. Third, iron overload surveillance should begin early in any child receiving regular transfusions, because cardiac and hepatic toxicity can develop silently. Finally, the developmental and psychosocial impact of chronic disease deserves equal attention; growth, school performance, and family stress are as much part of the clinical picture as the hemoglobin value.
Limitations of current knowledge include the incomplete understanding of genotype–phenotype correlations in many membrane disorders, the still-limited pediatric data on newer agents such as mitapivat, and the long-term durability and safety of gene therapies. Research priorities therefore encompass broader access to genetic testing, age-appropriate formulations of existing drugs, and carefully designed trials that include the youngest patients.
In the consulting room the challenge is both technical and human. A precise molecular diagnosis brings clarity, yet the child’s daily experience—fatigue, school absences, the fear of another crisis—remains the measure of success. When red cells break too soon, the task of the pediatric team is to restore not only hemoglobin but the ordinary rhythms of childhood growth and development. With earlier recognition, rational supportive care, and the expanding therapeutic armamentarium, that goal is increasingly attainable.
References
World Health Organization. WHO consolidated guidelines for the management of common childhood illness: management of sickle-cell disease in children and adolescents. Geneva: WHO; 2026.
Kalfa TA. Hereditary spherocytosis. UpToDate. Updated September 2026.
Grace RF, Barcellini W. Management of pyruvate kinase deficiency in children and adults. Blood. 2020;136(11):1241-1249.
Luke N, Hillier K, Al-Samkari H, Grace RF. Updates and advances in pyruvate kinase deficiency. Trends Mol Med. 2023;29(5):406-418.
Gallagher PG. Diagnosis and treatment of red cell membrane disorders: algorithm for the general hematologist. Hematology & Oncology. 2025.
Hartzell C, et al. Diagnosis and management of prenatal hereditary pyropoikilocytosis. Prenat Diagn. 2025.
Agarwal AM. Molecular diagnosis of hereditary hemolytic anemias: recent updates. Int J Lab Hematol. 2023.
Ware RE, et al. The modern use of hydroxyurea for children with sickle cell anemia. Haematologica. 2025;110(5):1061-1073.
WHO. Paediatric drug optimization for sickle cell disease: meeting report. Geneva: WHO; 2026.
Christensen RD, Yaish HM, Gallagher PG. A pediatrician’s practical guide to diagnosing and treating hereditary spherocytosis in neonates. Pediatrics. 2015;135(6):1107-1114.